Aeglea BioTherapeutics terminates Austin office lease, pays $2M termination fee

Spyre Therapeutics, Inc.

Terminated lease for Suites 100, 110, and 150 at 805 Las Cimas Parkway, Austin, TX effective Aug 8, 2023.
Lease originally dated April 30, 2019, amended Oct 2019 and Jan 2020; terminated via agreement with Landlord Las Cimas Owner LP.
Company paid a termination fee of $2 million as consideration for release from all future obligations under the lease.
No further obligations to Landlord arise or accrue from and after the Termination Date.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Spyre Therapeutics, Inc. terminated Lease Agreement dated April 30, 2019, as amended with Las Cimas Owner LP valued at Termination fee of $2,000,000 (effective 2023-08-08).

Action: termination
Agreement: lease
Counterparty: Las Cimas Owner LP
Value: Termination fee of $2,000,000
Effective: 2023-08-08

Exact text from the filing

On August 7, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) entered into a lease termination agreement (the “Termination Agreement”) with Las Cimas Owner LP (the “Landlord”) pursuant to which the parties agreed to terminate, as of August 8, 2023 (the “Termination Date”), that certain Lease Agreement dated as of April 30, 2019, as amended on October 2, 2019 and January 14, 2020 (the “Lease”), by and between the Landlord and the Company, pursuant to which the Company leased Suites 100, 110 and 150 located in the office building commonly known as 805 Las Cimas Parkway, Austin, Texas 78746 (the “Premises”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.